Journal article
National Working Group Meeting on ALK diagnostics in lung cancer
W Cooper, S Fox, S O'Toole, A Morey, G Frances, N Pavlakis, K O'Byrne, A Dettrick, T Leong, V Rathi, D Spagnolo, C Hemmings, M Singh, D Moffat, MS Tsao, K Wilner, R Buller, S Pitman Lowenthal, S Arifeen, J Binko Show all
Asia Pacific Journal of Clinical Oncology | WILEY | Published : 2014
DOI: 10.1111/ajco.12190
Abstract
The global landscape of molecular testing is rapidly changing, with the recent publication of the International Association for the Study of Lung Cancer (IASLC)/College of American Pathologists (CAP) guidelines and the ALK Atlas. The IASLC/CAP guidelines recommend that tumors from patients with non-small cell lung cancer (NSCLC) be tested for ALK rearrangements in addition to epidermal growth factor receptor (EGFR) mutations. The spur for this recommendation is the availability of novel therapies that target these rearrangements. This article is based on coverage of a Pfizer-sponsored National Working Group Meeting on ALK Diagnostics in Lung Cancer, held around the 15th World Lung Cancer Con..
View full abstractGrants
Funding Acknowledgements
This meeting was organized and funded by Pfizer Oncology and was conducted in accordance with Medicines Australia Code of Conduct. Dr Mahmood Alam from Pfizer designed the program, facilitated and reviewed the content of the presentations and the manuscript. Publication of this supplement has been supported through an independent educational grant from Pfizer Oncology. A medical writer undertook the writing of the first draft and coordinated author amendments. Wendy Cooper, Stephen Fox, Sandra O'Toole, Adrienne Morey, Glenn Frances, Nick Pavlakis, Kenneth O'Byrne, Andrew Dettrick, Trishe Leong, Vivek Rathi, Christine Hemmings, Mahendra Singh, David Moffat, Ming-Sound Tsao, have received honoraria and/or research funding from Pfizer Inc. Detailed disclosures are specified: Dominic Spagnolo has not received any honorarium from Pfizer. Andrew Dettrick has not received any funding from Pfizer. Glenn Francis received travel funding only, the honoraria was paid to employer. Stephen Fox's honorarium was paid to his institution. Vivek Rathi's honorarium was paid to his institution. Trisha Leong's honararium was paid to her institution.